Bim directly antagonizes Bcl-xl in doxorubicin-induced prostate cancer cell apoptosis independently of p53

References

• Yang F, Teves SS, Kemp CJ, Henikoff S. Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Biophys Acta 2014; 1845(1):84-9; PMID:24361676
   PubMed Web of Science ®Google Scholar
• Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, Altman RB. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 2011; 21(7):440-6; PMID:21048526; http://dx.doi.org/10.1097/FPC.0b013e32833ffb56
   PubMed Web of Science ®Google Scholar
• Forrest RA, Swift LP, Rephaeli A, Nudelman A, Kimura K, Phillips DR, Cutts SM. Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation. Biochem Pharmacol 2012; 83(12):1602-12; PMID:22414726; http://dx.doi.org/10.1016/j.bcp.2012.02.026
   PubMed Web of Science ®Google Scholar
• Coldwell KE, Cutts SM, Ognibene TJ, Henderson PT, Phillips DR. Detection of Adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations. Nucleic Acids Res 2008; 36(16):e100; PMID:18632763; http://dx.doi.org/10.1093/nar/gkn439
   PubMed Web of Science ®Google Scholar
• Strigun A, Wahrheit J, Niklas J, Heinzle E, Noor F. Doxorubicin increases oxidative metabolism in HL-1 cardiomyocytes as shown by 13C metabolic flux analysis. Toxicol Sci 2012; 125(2):595-606; PMID:22048646; http://dx.doi.org/10.1093/toxsci/kfr298
   PubMed Web of Science ®Google Scholar
• Myers C. The role of iron in doxorubicin-induced cardiomyopathy. Semin Oncol 1998; 25(4 Suppl 10):10-4; PMID:9768818
   PubMed Web of Science ®Google Scholar
• Yang F, Kemp CJ, Henikoff S. Doxorubicin enhances nucleosome turnover around promoters. Curr Biol 2013; 23(9):782-7; PMID:23602475; http://dx.doi.org/10.1016/j.cub.2013.03.043
   PubMed Web of Science ®Google Scholar
• Weber AM, Ryan AJ. ATM and ATR as therapeutic targets in cancer. Pharmacol Ther 2015; 149:124-38; PMID:25512053; http://dx.doi.org/10.1016/j.pharmthera.2014.12.001
   PubMed Web of Science ®Google Scholar
• Cremona CA, Behrens A. ATM signalling and cancer. Oncogene 2014; 33(26):3351-60; PMID:23851492; http://dx.doi.org/10.1038/onc.2013.275
   PubMed Web of Science ®Google Scholar
• Zeman MK, Cimprich KA. Causes and consequences of replication stress. Nat Cell Biol 2014; 16(1):2-9; PMID:24366029; http://dx.doi.org/10.1038/ncb2897
   PubMed Web of Science ®Google Scholar
• Shiloh Y, Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol 2013; 14(4):197-210; http://dx.doi.org/10.1038/nrm3546
   Web of Science ®Google Scholar
• Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB, Siliciano JD. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 1998; 281(5383):1677-9; PMID:9733515; http://dx.doi.org/10.1126/science.281.5383.1677
   PubMed Web of Science ®Google Scholar
• Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998; 281(5383):1674-7; PMID:9733514; http://dx.doi.org/10.1126/science.281.5383.1674
   PubMed Web of Science ®Google Scholar
• Smith J, Tho LM, Xu N, Gillespie DA. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 2010; 108:73-112; PMID:21034966; http://dx.doi.org/10.1016/B978-0-12-380888-2.00003-0
   PubMed Web of Science ®Google Scholar
• Hofmann TG, Glas C, Bitomsky N. HIPK2: A tumour suppressor that controls DNA damage-induced cell fate and cytokinesis. Bioessays 2013; 35(1):55-64; PMID:23169233; http://dx.doi.org/10.1002/bies.201200060
   PubMed Web of Science ®Google Scholar
• Sullivan KD, Gallant-Behm CL, Henry RE, Fraikin JL, Espinosa JM. The p53 circuit board. Biochim Biophys Acta 2012; 1825(2):229-44; PMID:22333261
   PubMed Web of Science ®Google Scholar
• Choi M, Shi J, Jung SH, Chen X, Cho KH. Attractor landscape analysis reveals feedback loops in the p53 network that control the cellular response to DNA damage. Sci Signal 2012; 5(251):ra83; PMID:23169817; http://dx.doi.org/10.1126/scisignal.2003363
   PubMed Web of Science ®Google Scholar
• Khoo KH, Verma CS, Lane DP. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov 2014; 13(3):217-36; PMID:24577402; http://dx.doi.org/10.1038/nrd4236
   PubMed Web of Science ®Google Scholar
• Cazzalini O, Scovassi AI, Savio M, Stivala LA, Prosperi E. Multiple roles of the cell cycle inhibitor p21(CDKN1A) in the DNA damage response. Mutat Res 2010; 704(1-3):12-20; PMID:20096807; http://dx.doi.org/10.1016/j.mrrev.2010.01.009
   PubMed Web of Science ®Google Scholar
• Happo L, Cragg MS, Phipson B, Haga JM, Jansen ES, Herold MJ, Dewson G, Michalak EM, Vandenberg CJ, Smyth GK, et al. Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim. Blood 2010; 116(24):5256-67; PMID:20829369; http://dx.doi.org/10.1182/blood-2010-04-280818
   PubMed Web of Science ®Google Scholar
• Kracikova M, Akiri G, George A, Sachidanandam R, Aaronson SA. A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis. Cell Death Differ 2013; 20(4):576-88; PMID:23306555; http://dx.doi.org/10.1038/cdd.2012.155
   PubMed Web of Science ®Google Scholar
• Doerflinger M, Glab JA, Puthalakath H. BH3-only proteins: a 20-year stock-take. FEBS J 2015; 282(6):1006-16; PMID:25565426; http://dx.doi.org/10.1111/febs.13190
   PubMed Web of Science ®Google Scholar
• van Delft MF, Huang DC. How the Bcl-2 family of proteins interact to regulate apoptosis. Cell Res 2006; 16(2):203-13; PMID:16474435; http://dx.doi.org/10.1038/sj.cr.7310028
   PubMed Web of Science ®Google Scholar
• Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM, Huang DC. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17(3):393-403; PMID:15694340; http://dx.doi.org/10.1016/j.molcel.2004.12.030
   PubMed Web of Science ®Google Scholar
• Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 2010; 11(9):621-32; PMID:20683470; http://dx.doi.org/10.1038/nrm2952
   PubMed Web of Science ®Google Scholar
• Bertheau P, Turpin E, Rickman DS, Espie M, de Reynies A, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt A, et al. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med 2007; 4(3):e90; PMID:17388661; http://dx.doi.org/10.1371/journal.pmed.0040090
   PubMed Web of Science ®Google Scholar
• Bertheau P, Plassa F, Espie M, Turpin E, de Roquancourt A, Marty M, Lerebours F, Beuzard Y, Janin A, de Thé H. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 2002; 360(9336):852-4; PMID:12243922; http://dx.doi.org/10.1016/S0140-6736(02)09969-5
   PubMed Web of Science ®Google Scholar
• Jackson JG, Pant V, Li Q, Chang LL, Quintas-Cardama A, Garza D, Tavana O, Yang P, Manshouri T, Li Y, et al. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 2012; 21(6):793-806; PMID:22698404; http://dx.doi.org/10.1016/j.ccr.2012.04.027
   PubMed Web of Science ®Google Scholar
• Wang C, Huang SB, Yang MC, Lin YT, Chu IH, Shen YN, Chiu YH, Hung SH, Kang L, Hong YR, et al. Combining paclitaxel with ABT-263 has a synergistic effect on paclitaxel resistant prostate cancer cells. PloS One 2015; 10(3):e0120913; PMID:25811469; http://dx.doi.org/10.1371/journal.pone.0120913
   PubMed Web of Science ®Google Scholar
• Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68(9):3421-8; PMID:18451170; http://dx.doi.org/10.1158/0008-5472.CAN-07-5836
   PubMed Web of Science ®Google Scholar
• Dey P, Strom A, Gustafsson JA. Estrogen receptor β upregulates FOXO3a and causes induction of apoptosis through PUMA in prostate cancer. Oncogene 2014; 33(33):4213-25; PMID:24077289; http://dx.doi.org/10.1038/onc.2013.384
   PubMed Web of Science ®Google Scholar
• Castilla C, Congregado B, Chinchon D, Torrubia FJ, Japon MA, Saez C. Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak. Endocrinology 2006; 147(10):4960-7; PMID:16794010; http://dx.doi.org/10.1210/en.2006-0502
   PubMed Web of Science ®Google Scholar
• Liu D, Tao T, Xu B, Chen S, Liu C, Zhang L, Lu K, Huang Y, Jiang L, Zhang X, et al. MiR-361-5p acts as a tumor suppressor in prostate cancer by targeting signal transducer and activator of transcription-6(STAT6). Biochem Biophys Res Commun 2014; 445(1):151-6; PMID:24491557; http://dx.doi.org/10.1016/j.bbrc.2014.01.140
   PubMed Web of Science ®Google Scholar
• Das S, Roth CP, Wasson LM, Vishwanatha JK. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer. Prostate 2007; 67(14):1550-64; PMID:17705178; http://dx.doi.org/10.1002/pros.20640
   PubMed Web of Science ®Google Scholar
• Parrondo R, de Las Pozas A, Reiner T, Perez-Stable C. ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells. PeerJ 2013; 1:e144; PMID:24058878; http://dx.doi.org/10.7717/peerj.144
   PubMed Web of Science ®Google Scholar
• Kutuk O, Letai A. Displacement of Bim by Bmf and Puma rather than increase in Bim level mediates paclitaxel-induced apoptosis in breast cancer cells. Cell Death Differ 2010; 17(10):1624-35; PMID:20431602; http://dx.doi.org/10.1038/cdd.2010.41
   PubMed Web of Science ®Google Scholar